Pradeep B J Reddy
Overview
Explore the profile of Pradeep B J Reddy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
713
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bollimpelli V, Reddy P, Gangadhara S, Charles T, Burton S, Tharp G, et al.
Nat Commun
. 2023 Aug;
14(1):4789.
PMID: 37553348
Route of immunization can markedly influence the quality of immune response. Here, we show that intradermal (ID) but not intramuscular (IM) modified vaccinia Ankara (MVA) vaccinations provide protection from acquisition...
2.
Styles T, Gangadhara S, Reddy P, Sahoo A, Shiferaw A, Welbourn S, et al.
Front Immunol
. 2022 Aug;
13:914969.
PMID: 35935987
Stabilized HIV envelope (Env) trimeric protein immunogens have been shown to induce strong autologous neutralizing antibody response. However, there is limited data on the immunogenicity and efficacy of stabilized Env...
3.
Murugesan A, Ibegbu C, Styles T, Jones A, Shanmugasundaram U, Reddy P, et al.
Front Immunol
. 2020 Feb;
10:3053.
PMID: 32010135
Mucosa-associated invariant T (MAIT) cells are recently characterized as a novel subset of innate-like T cells that recognize microbial metabolites as presented by the MHC-1b-related protein MR1. The significance of...
4.
Chamcha V, Reddy P, Kannanganat S, Wilkins C, Gangadhara S, Velu V, et al.
Sci Transl Med
. 2019 Nov;
11(519).
PMID: 31748228
Activated CD4 T cells are a major target of HIV infection. Results from the STEP HIV vaccine trial highlighted a potential role for total activated CD4 T cells in promoting...
5.
Styles T, Gangadhara S, Reddy P, Hicks S, LaBranche C, Montefiori D, et al.
J Virol
. 2019 Jul;
93(20).
PMID: 31341049
The RV144 human immunodeficiency virus type 1 (HIV-1) vaccine trial showed a strong association between anti-gp70 V1V2 scaffold (V1V2) and anti-V2 hot spot peptide (V2 HS) antibody responses and reduced...
6.
Burton S, Spicer L, Charles T, Gangadhara S, Reddy P, Styles T, et al.
J Virol
. 2019 Jan;
93(7).
PMID: 30651354
The goals of preclinical HIV vaccine studies in nonhuman primates are to develop and test different approaches for their ability to generate protective immunity. Here, we compared the impact of...
7.
Varanasi S, Reddy P, Bhela S, Jaggi U, Gimenez F, Rouse B
J Virol
. 2017 Jan;
91(7).
PMID: 28100624
Ocular infection with herpes simplex virus 1 (HSV-1) sets off an inflammatory reaction in the cornea which leads to both virus clearance and chronic lesions that are orchestrated by CD4...
8.
Kannanganat S, Wyatt L, Gangadhara S, Chamcha V, Chea L, Kozlowski P, et al.
J Immunol
. 2016 Sep;
197(9):3586-3596.
PMID: 27683750
We tested, in rhesus macaques, the effects of a 500-fold range of an admixed recombinant modified vaccinia Ankara (MVA) expressing rhesus GM-CSF (MVA/GM-CSF) on the immunogenicity and protection elicited by...
9.
Iyer S, Gangadhara S, Victor B, Shen X, Chen X, Nabi R, et al.
J Virol
. 2016 Jul;
90(19):8842-54.
PMID: 27466414
Unlabelled: The encouraging results of the RV144 vaccine trial have spurred interest in poxvirus prime-protein boost human immunodeficiency virus (HIV) vaccine modalities as a strategy to induce protective immunity. Because...
10.
Bhela S, Mulik S, Gimenez F, Reddy P, Richardson R, Varanasi S, et al.
Am J Pathol
. 2015 Feb;
185(4):1073-84.
PMID: 25700796
Ocular infection with herpes simplex virus 1 can result in a chronic immunoinflammatory stromal keratitis (SK) lesion that is a significant cause of human blindness. A key to controlling SK...